In the Clinic
Our lead investigational drug, OP-1250, is an estrogen receptor antagonist. It was developed to compete with estrogen for binding to the receptor and keep it in a completely inactive state.
OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+, HER2- MBC), in both monotherapy and combination settings.
OP-1250 Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Metastatic Breast Cancer
ER+, HER2- MBC (with and without CNS metastases)
ER+, HER2- MBC (combination with palbociclib)
ER+, HER2- MBC (combination with ribociclib)
ER+, HER2- MBC with PIK3CA mutated (combination with alpelisib)
ER+ with ESR1 mutation(1)
HER2+ Metastatic Breast Cancer with CNS METS
ER+, HER2+ MBC with CNS metastases
Gynecology — Oncology
Endometrial Cancer(1)
Gynecologic malignancies
Discovery Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Breast Cancer target
Undisclosed Oncology target